Dr Simon Stott
Simon is Director of Research at Cure Parkinson’s.
Simon leads on fostering promising new lines of research, promoting beneficial worldwide scientific and clinical collaborations across the community. Simon plays a leading role in the ongoing growth of Cure Parkinson’s International Linked Clinical Trials (iLCT) programme, working alongside the iLCT Committee to ensure the most promising drugs are prioritised for clinical trial in Parkinson’s.
Articles by Dr Simon Stott
The Phase 3 Exenatide results
Since the results of a Phase 2b clinical trial were published in 2017, the Parkinson’s community has focused a lot of attention on a class of diabetes drugs called Glucagon-like peptide-1 (or GLP-1) agonists. Last year, the results of another Phase 2 GLP-1 agonist study in Parkinson’s provided further encouraging data. And […]
The road ahead: 2025 (part 1)
The first post at the start of each year on the SoPD website has traditionally tried to provide an overview or some context on where things are in the search for ‘disease modifying’ therapies for Parkinson’s. Previous editions of the “Road Ahead” posts have become dangerously overloaded, unwieldy, chaotic one-page beasts, […]
Cure Parkinson’s Autumn Research Update meeting – 2023
Cure Parkinson’s is a medical research charity that is focused on disease modification for Parkinson’s. Our only goal is to slow, stop or reverse the condition. To achieve this aim, we fund and support preclinical projects (that are with 5 years of clinical testing) and clinical trials focused on testing new […]
The UP Study results
Preclinical data have suggested that the bile acid Ursodeoxycholic acid (or UDCA) has neuroprotective properties in models of Parkinson’s. Researchers in Sheffield have led much of this research and they have also been coordinating a clinical trial assessing this molecule in people with Parkinson’s. The study was called the “UDCA in […]